Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

COVID-19: combining antiviral and anti-inflammatory treatments

(2020) Justin Stebbing et al.   LANCET INFECTIOUS DISEASES

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports

(2020) Valeria Gaspari et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

(2020) Danielle Peterson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

(2019) Asra Ahmed et al.   Lancet Haematology

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE